



# LANXESS – Q2 2011 Results Conference Call

**Strong pricing and volume increase**

Dr. Axel C. Heitmann, CEO

Dr. Bernhard Düttmann, CFO

# Safe harbor statement

This presentation contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the company to differ materially from the estimations expressed or implied herein. The company does not guarantee that the assumptions underlying such forward looking statements are free from errors nor do they accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecasted developments. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

# Agenda

- Executive overview Q2 2011
- Business and financial review Q2 2011
- Outlook/Guidance

# Highlights Q2 2011

## Ongoing strong operational performance

**23% sales growth, based on strong pricing and volume increase in tandem**

**Acquisition-related sales growth of 5% - EPDM business integration on track**

**Substantially higher raw material prices (mainly Butadiene) fully offset**

**EBITDA increases by 26% with stable margins**

**Year-to-date earnings per share reach €4.17**

# LANXESS – well positioned for the future

## Regional diversity



- World-wide presence
- Global manufacturing network
- Targeted investment in growth markets
- Well positioned in growth regions (Brazil, India, China)

## Megatrends intact



- Mobility - growing population and middle-class in Asia and LatAm
- Agro - increasing crop demand based on growing world population
- Urbanization - growing cities
- Water - scarcity of purified water

## Premium Products



- Global technology leader in synthetic rubbers and polyamide based high-tech plastics
- Leading supplier of agchem intermediate building blocks
- Specialty chemicals with strong brands and technology position

**Geopolitical and macroeconomic uncertainties remain**

# Successful pricing strategy for more than six years








Chart 6

# Tire labeling – a global trend fueled by need of resource efficiency

Region	EU	Japan	South Korea	US	China	Mexico	Brazil
Tire labeling performance attributes							
Traction (Wet Grip)	Nov 2012	since 2010	Nov 2011	in discussion	Regulatory initiatives expected		
Fuel economy (Cost of Ownership)	Nov 2012	since 2010	Nov 2011	in discussion			
Treadlife (Cost of Ownership)	-	Not expected	Not expected	in discussion			

Source: EU regulation no. 1222/2009, National Highway Traffic Safety Administration (NHTSA), Japan Automobile Tyre Manufacturers Association (JATMA), Korea Energy Management Corporation (KEMCO), LANXESS

Chart 7




# Massive selling price increase continues to offset raw material price hikes

Q2 yoy sales variances	Price	Volume	Currency	Portf.	Total
Performance Polymers	29%	9%	-9%	9%	37%
Advanced Intermediates	9%	10%	-4%	0%	14%
Performance Chemicals	8%	-1%	-5%	2%	5%
<b>LANXESS</b>	<b>19%</b>	<b>6%</b>	<b>-7%</b>	<b>5%</b>	<b>23%</b>

- Substantial price increases in tandem with volume growth in two segments
- Adverse currency effects
- Positive portfolio effects from recent acquisitions

## Q2 yoy EBITDA bridge [€m]




- Pricing offsets significantly higher input costs, “price-before-volume” strategy intact
- “Others” mainly reflects currency effects as well as absence of savings

Chart 8



# Substantial growth in all regions



\* currency and portfolio adjusted

Chart 9

# Agenda

- Executive overview Q2 2011
- Business and financial review Q2 2011
- Outlook/Guidance

# Q2 2011 financials: strong portfolio yielding strong results

[€m]	Q2 2010	Q2 2011	yoy in %	
Sales	1,828	2,243	22.7%	<ul style="list-style-type: none"> <li>▪ Ongoing strong demand reflected in sales growth</li> <li>▪ Higher EBITDA margin due to “price-before-volume” strategy despite PPA effect (EPDM)</li> <li>▪ Capex increases as growth projects proceed</li> </ul>
EBITDA pre except. margin	269 14.7%	339 15.1%	26.0%	
EPS	1.57	2.17	38.2%	
Capex*	60	109	81.7%	
[€m]	31.12.2010	30.06.2011	% vs. YE	
Net Financial Debt	913	1,364	49.4%	<ul style="list-style-type: none"> <li>▪ Net debt rises after acquisitions</li> <li>▪ Working capital increase driven by pricing, portfolio and stronger business activity</li> <li>▪ Headcount increase mainly due to recent acquisitions</li> </ul>
Net Working Capital	1,372	1,827	33.2%	
Employees	14,648	15,820	8.0%	

**Another strong quarter of good margins and EBITDA increase**

\* net of projects financed by customers and capitalized borrowing costs

Chart 11

**LANXESS**


# Price-before-volume strategy and excellent market positions boost earnings

[€m]	Q2 2010	Q2 2011	yoy in %	
<b>Sales</b>	<b>1,828 (100%)</b>	<b>2,243 (100%)</b>	<b>23%</b>	<ul style="list-style-type: none"> <li>▪ Sales up 23% due to strong price (+19%) and volume (+6%) effects. Portfolio (+5%) almost offsets negative currency effects (-7%)</li> <li>▪ Effects from purchase price allocation included in cost of sales</li> <li>▪ Earnings expansion with good margins</li> <li>▪ EPS and EBITDA increase on the basis of healthy pricing, compensating raw material inflation</li> </ul>
Cost of sales	-1,354 (74%)	-1,704 (76%)	26%	
Selling	-162 (9%)	-187 (8%)	15%	
G&A	-67 (4%)	-74 (3%)	10%	
R&D	-31 (2%)	-34 (2%)	10%	
<b>EBIT</b>	<b>196 (11%)</b>	<b>255 (11%)</b>	<b>30%</b>	
<b>Net Income</b>	<b>131 (7%)</b>	<b>181 (8%)</b>	<b>38%</b>	
<b>EPS</b>	<b>1.57</b>	<b>2.17</b>	<b>38%</b>	
EBITDA	265 (14%)	334 (15%)	26%	
thereof exceptionals	-4 (0%)	-5 (0%)	25%	
<b>EBITDA pre exceptionals</b>	<b>269 (15%)</b>	<b>339 (15%)</b>	<b>26%</b>	


**Strong earnings generation**

**LANXESS**

# Q2 2011 – Performance Polymers drive sales, EBITDA and margin increase



- Performance Polymers with strongest sales increase
- Advanced Intermediates and Performance Chemicals with slight sales growth



- Performance Polymers strongest contributor to year-on-year EBITDA increase
- Solid margins in all three segments


\* pre exceptionals

# Performance Polymers: continued strength of demand


[€m]	Q2 2010	Q2 2011
<b>Sales</b>	<b>935</b>	<b>1,281</b>
EBIT	126	191
Depr. / Amort.	37	38
EBITDA	163	229
<b>EBITDA pre exceptionals</b>	<b>164</b>	<b>229</b>
Margin	17.5%	17.9%
<b>Capex*</b>	<b>32</b>	<b>72</b>

- All BUs manage price increases to offset risen raw material prices (notably Butadiene, Isobutylene)
- Healthy end-market demand reflected in solid volume increase
- Continued positive mix-effect in BU PBR (more Nd-PBR, SSBR)
- EPDM integration on track, PPA inventory effect fully included
- BU SCP expansion activities completed according to plan
- EBITDA benefits from positive pricing levels; margins remain at high level of previous year
- Planned rise of Capex for Singapore, significant further increase planned in H2

Sales by BU



Sales bridge year on year [€ m]




\* net of capitalized borrowing costs

# Advanced Intermediates: absolute performance in line with previous year's high level


[€m]	Q2 2010	Q2 2011
<b>Sales</b>	<b>347</b>	<b>395</b>
EBIT	53	47
Depr. / Amort.	14	18
EBITDA	67	65
<b>EBITDA pre exceptionals</b>	<b>67</b>	<b>65</b>
Margin	19.3%	16.5%
<b>Capex*</b>	<b>7</b>	<b>20</b>

- Price and volume increases overcompensate negative currency development
- BU SGO with increased demand from agro end-markets
- Expansion of cresol train at BU Advanced Industrial Intermediates as well as agro-related demand fuels volume growth
- Stable absolute EBITDA, but comparably lower margin due to delayed pricing pattern in Q2 2010
- Higher Capex from expansion in BU All (chlorotoluenes and cresols)

## Sales by BU



## Sales bridge year on year [€ m]




\* net of projects financed by customers

# Performance Chemicals: price-before-volume pays off


[€m]	Q2 2010	Q2 2011
<b>Sales</b>	<b>537</b>	<b>561</b>
EBIT	67	76
Depr. / Amort.	17	19
EBITDA	84	95
<b>EBITDA pre exceptionals</b>	<b>84</b>	<b>95</b>
Margin	15.6%	16.9%
<b>Capex</b>	<b>18</b>	<b>14</b>

- Sales increase due to positive price and portfolio effects mitigated by negative currency and volume developments
- Strict adherence to “price-before-volume” strategy leads to EBITDA and margin increase
- All business units with price increases
- BU IPG & RUC with strongest contribution to EBITDA growth
- BU LEA benefits from chrome ore pricing, however offset by disruptions in production due to industry strikes in South-Africa and Argentina weighing on volumes
- Seasonal softening in H2 expected

Sales by BU



Sales bridge year on year [€ m]





# Solid financial position

[€m]	Dec 31, 2010	Jun 30, 2011		Dec 31, 2010	Jun 30, 2011
<b>Non-current Assets</b>	<b>2,738</b>	<b>3,056</b>	<b>Stockholders' Equity</b>	<b>1,761</b>	<b>2,034</b>
Intangible assets	226	355	<b>Non-current Liabilities</b>	<b>2,454</b>	<b>2,531</b>
Property, plant & equipment	2,131	2,286	Pension & post empl. provis.	605	610
Equity investments	13	28	Other provisions	351	321
Other investments	8	36	<b>Other financial liabilities</b>	<b>1,302</b>	<b>1,393</b>
Other financial assets	74	74	Tax liabilities	50	51
Deferred taxes	170	140	Other liabilities	106	90
Other non-current assets	116	137	Deferred taxes	40	66
<b>Current Assets</b>	<b>2,928</b>	<b>3,532</b>	<b>Current Liabilities</b>	<b>1,451</b>	<b>2,023</b>
Inventories	1,094	1,364	Other provisions	422	448
Trade accounts receivable	942	1,227	<b>Other financial liabilities</b>	<b>176</b>	<b>587</b>
Other financial & current assets	368	346	Trade accounts payable	664	764
Near cash assets	364	310	Tax liabilities	34	87
Cash and cash equivalents	160	285	Other liabilities	155	137
<b>Total Assets</b>	<b>5,666</b>	<b>6,588</b>	<b>Total Equity &amp; Liabilities</b>	<b>5,666</b>	<b>6,588</b>

- Balance sheet reflects DSM-EPDM acquisition
- Other non-current financial liabilities include new €500 m bond while current financial liabilities now comprise €400 m bond
- Higher inventories from increased business activity, rising raw material prices and DSM-EPDM acquisition

# Strong operating cash generation vs. acquisition cash-outs

[€m]	H1 2010	H1 2011	
<b>Profit before Tax</b>	<b>316</b>	<b>451</b>	
Depreciation & amortization	135	150	
Gain from sale of assets	0	-2	
Result from equity investments	-12	-12	
Financial losses	40	43	
Cash tax payments / refunds	-28	-6	
Changes in other assets and liabilities	-41	-10	
<b>Operating Cash Flow before changes in WC</b>	<b>410</b>	<b>614</b>	
Changes in Working Capital	-350	-366	
<b>Operating Cash Flow</b>	<b>60</b>	<b>248</b>	
<b>Investing Cash Flow</b>	<b>101</b>	<b>-351</b>	
thereof Capex	-99	-177	
<b>Financing Cash Flow</b>	<b>-247</b>	<b>234</b>	

- Cash flow fueled by demand momentum
- Working capital increase driven by higher receivables and inventories (volumes as well as raw material induced pricing)
- Investing cash flow contains cash-outs for acquisitions (in TRP, MPP and RCH)
- Financing cash-flow mirrors €500 m bond partly offset by dividends, interest & settlement of acquisition related debt

**Solid operating cash-flow contribution**

# Agenda

- Executive overview Q2 2011
- Business and financial review Q2 2011
- Outlook/Guidance


# LANXESS lifts EBITDA guidance for 2011: ~ 20% growth

## Current macro view

- Growth in emerging markets to continue, albeit at slower pace
- Germany with solid growth prospects, other Western economies continue to grow slowly
- Macroeconomic challenges: potential impact related to uncertainties over high national deficits in some European states, US dollar weakness

## LANXESS remains optimistic for 2011

- We expect return to normal seasonality of our customer industries
- Several organic growth projects and recent acquisitions as well as strong market positions provide a good base for continued growth
- Focused and disciplined growth continued
- We lift earnings\* growth from 10 - 15% to ~20%



\* EBITDA pre exceptionals

Chart 20

**LANXESS**

**LANXESS**

Energizing Chemistry



# Appendix

# 2011 financial expectations

## Additional financial expectations for 2011

- Capex : ~€550-600 m
- D&A : ~€300 – €320 m incl. acquisition
- Tax rate : 20 to 25%
- Hedging 2011 : ~40% at 1.30-1.40 USD / EUR




# All segments manage price and volume increases in tandem

H1 yoy sales variances	Price	Volume	Currency	Portf.	Total
Performance Polymers	26%	10%	-4%	5%	36%
Advanced Intermediates	9%	11%	-2%	0%	18%
Performance Chemicals	7%	5%	-2%	2%	13%
<b>LANXESS</b>	<b>17%</b>	<b>9%</b>	<b>-3%</b>	<b>3%</b>	<b>25%</b>

- Substantial price increases in tandem with volume growth in all segments
- Adverse currency effects
- Recent acquisitions reflected in positive portfolio effects

## H1 yoy EBITDA bridge [€m]



- Higher pricing offsets sharply rising input costs, “Price before volume” strategy intact
- “Others” mainly reflects currency effects as well as absence of savings

Chart 24



# H1 2011 financials: strong EBITDA and EPS increase

[€m]	H1 2010	H1 2011	yoy in %
Sales	3,441	4,316	25.4%
EBITDA pre except.	502	661	31.7%
margin	14.6%	15.3%	
EPS	2.82	4.17	47.9%
Capex*	99	177	78.8%

[€m]	31.12.2010	30.06.2011	% vs. YE
Net Financial Debt	913	1,364	49.4%
Net Working Capital	1,372	1,827	33.2%
Employees	14,648	15,820	8.0%

- Persisting strong demand reflected in sales growth
- Sustained EBITDA margin supported by strict adherence to “price-before-volume” strategy
- Capex increases as growth projects proceed
- Net debt rises after acquisitions
- Working capital increase driven by pricing, portfolio and risen business activity
- Headcount increase mainly due to recent acquisitions

**Solid demand, premium products and ongoing cost discipline yield an excellent H1 2011**

\* net of projects financed by customers and capitalized borrowing costs

Chart 25

**LANXESS**


# Strong pricing, healthy demand and tight cost control yield an excellent H1 2011

[€m]	H1 2010	H1 2011	yoy in %	
<b>Sales</b>	<b>3,441 (100%)</b>	<b>4,316 (100%)</b>	<b>25%</b>	<ul style="list-style-type: none"> <li>▪ Sales increase 25% due to strong price (+17%) and volume (+9%) effects. Portfolio (+3%) offsets negative currency effects (-3%)</li> <li>▪ Absolute operational cost base increases due to higher business activity and DSM-EPDM acquisition</li> <li>▪ Earnings expansion with stable margins on high level due to strong pricing compensating raw material inflation as well as volume gains</li> </ul>
Cost of sales	-2,573 (75%)	-3,255 (75%)	27%	
Selling	-304 (9%)	-357 (8%)	17%	
G&A	-127 (4%)	-144 (3%)	13%	
R&D	-55 (2%)	-65 (2%)	18%	
<b>EBIT</b>	<b>360 (10%)</b>	<b>501 (12%)</b>	<b>39%</b>	
<b>Net Income</b>	<b>235 (7%)</b>	<b>347 (8%)</b>	<b>48%</b>	
<b>EPS</b>	<b>2.82</b>	<b>4.17</b>	<b>48%</b>	
EBITDA	495 (14%)	651 (15%)	32%	
thereof exceptionals	-7 (0%)	-10 (0%)	43%	
<b>EBITDA pre exceptionals</b>	<b>502 (15%)</b>	<b>661 (15%)</b>	<b>32%</b>	


**Solid H1 2011**

**LANXESS**

# H1 2011 – Performance Polymers drive sales, EBITDA and margin increase



- Performance Polymers with strongest increase in sales
- Advanced Intermediates and Performance Chemicals with slight sales growth



- Performance Polymers strongest contributor to year on year EBITDA increase
- Solid margins in all three segments


\* pre exceptionals

# Performance Polymers: significant price increases are key ingredient for solid H1


[€m]	H1 2010	H1 2011
<b>Sales</b>	<b>1,741</b>	<b>2,365</b>
EBIT	222	356
Depr. / Amort.	71	72
EBITDA	293	428
<b>EBITDA pre exceptionals</b>	<b>295</b>	<b>428</b>
Margin	16.9%	18.1%
<b>Capex*</b>	<b>51</b>	<b>112</b>

- Price increases in all BUs, offsetting Butadiene-driven raw material price increase
- Healthy end-market demand reflected in solid volume increase
- PBR with positive mix effect from Nd-PBR as well as SSBR
- BU SCP expansion activities completed according to plan; EPDM integration on track
- EBITDA benefits from positive pricing levels; margins above high level of previous year
- Planned rise of Capex for Singapore, significant further increase planned in H2

Sales by BU



Sales bridge year on year [€ m]




\* net of capitalized borrowing costs

# Advanced Intermediates: agro-business drives earnings


[€m]	H1 2010	H1 2011
<b>Sales</b>	<b>689</b>	<b>811</b>
EBIT	96	106
Depr. / Amort.	28	34
EBITDA	124	140
<b>EBITDA pre exceptionals</b>	<b>124</b>	<b>140</b>
Margin	18.0%	17.3%
<b>Capex*</b>	<b>12</b>	<b>33</b>

- Price increases compensate significant raw material price inflation (Benzene)
- BUs All and SGO with overall strong volumes based on agro-related demand
- Additional volumes from expansion of cresol train at BU All
- EBITDA rises; margins mirror full price pass-through
- Higher Capex from expansion in BU Advanced Industrial Intermediates (chlorotoluenes and cresols)
- No summer-lull expected

Sales by BU



Sales bridge year on year [€m]



\* net of projects financed by customers

# BU Advanced Industrial Intermediates – highly efficient technologies and strong market positions




	Aromatic Network	Benzyl Products, Inorganic Acids	Polyols and Oxidation Products	A solid platform
Characteristics	<ul style="list-style-type: none"> <li>Dedicated assets within aromatic network</li> <li>Manufacturing of products highly connected</li> </ul>	<ul style="list-style-type: none"> <li>Dedicated assets within Benzyl Products and Inorganic Acids</li> <li>Manufacturing of products highly interconnected</li> </ul>	<ul style="list-style-type: none"> <li>Dedicated assets within Polyols and Oxidation Products</li> </ul>	<ul style="list-style-type: none"> <li>Strong positions in niche markets with many key products</li> <li>Cost advantage from world scale plants and competitive technologies</li> <li>Global reach with sites in Germany, India, US and China</li> <li>Aromatic Network with best in class isomer management</li> <li>Megatrends drive demand of key products</li> </ul>
Building blocks for end markets	<ul style="list-style-type: none"> <li>Agro</li> <li>Polymers</li> <li>Consumer products (Vitamin E, Menthol)</li> </ul>	<ul style="list-style-type: none"> <li>Agro</li> <li>Automotive (air conditioning, plastics)</li> <li>Flavors &amp; Fragrances</li> </ul>	<ul style="list-style-type: none"> <li>Coatings (Auto, Paints)</li> <li>Polyester Resins</li> </ul>	
				


Chart 30

# Performance Chemicals: strong volume and price performance

[€m]	H1 2010	H1 2011
<b>Sales</b>	<b>922</b>	<b>1,117</b>
EBIT	129	148
Depr. / Amort.	33	37
EBITDA	162	185
<b>EBITDA pre exceptionals</b>	<b>162</b>	<b>185</b>
Margin	16.3%	16.6%
<b>Capex</b>	<b>32</b>	<b>28</b>

- Volume and price developments lead to stronger sales, raw materials offset by price increases
- All business units with price increases
- IPG and RUC are strongest contributors to EBITDA increase
- LEA benefits from chrome ore pricing, however offset by disruptions in production due to industry strikes in South-Africa and Argentina weighing on volumes
- Strict adherence to “price-before-volume” strategy leads to EBITDA and margin increase
- Limited summer weakness – normal H2 seasonality expected

Sales by BU



Sales bridge year on year [€ m]




Chart 31

# Strong operating cash generation vs. acquisition cash-outs

[€m]	Q2 2010	Q2 2011	
<b>Profit before Tax</b>	<b>172</b>	<b>232</b>	<ul style="list-style-type: none"> <li>▪ Profit before tax drives operating cash-flow</li> <li>▪ Working capital increase due to higher receivables and inventories (raw material induced pricing and volumes)</li> <li>▪ Investing cash flow contains cash-outs for acquisitions (in TRP, MPP)</li> <li>▪ Financing cash-flow mirrors €500 m bond partly offset by dividends, interest &amp; settlement of acquisition related debt</li> </ul>
Depreciation & amortization	69	79	
Gain from sale of assets	0	-2	
Result from equity investments	-8	-7	
Financial losses	19	23	
Cash tax payments / refunds	-10	-10	
Changes in other assets and liabilities	-39	-38	
<b>Operating Cash Flow before changes in WC</b>	<b>203</b>	<b>277</b>	
Changes in Working Capital	-135	-65	
<b>Operating Cash Flow</b>	<b>68</b>	<b>212</b>	
<b>Investing Cash Flow</b>	<b>140</b>	<b>-332</b>	
thereof Capex	-60	-109	
<b>Financing Cash Flow</b>	<b>-190</b>	<b>241</b>	

**Solid operating cash-flow contribution**




# A well managed and conservative maturity profile

## Long term financing secured

- Well balanced maturity profile
- Diversified financing sources
  - Bonds & bilateral credit lines
  - Syndicated Revolving Credit Facility
  - Development banks
- New financing source:
  - € 200 m long-term credit facility for up to seven years for R&D financing from EIB\*

## Liquidity and maturity profile as per June 2011




\* European Investment Bank; \*\*Final maturity of EIB financing in case of utilization in 2016 or later; EIB facility currently undrawn

Chart 33

# Increase in raw material prices expected to continue

Global raw materials index\*



- Raw material prices increase since the start of 2010
- Q3 and Q4 '10 with a relatively stable raw material price development
- H1 saw feedstock prices (mainly butadiene, benzene and cyclohexane) rise, feedstocks set to increase even further in Q3

**LANXESS committed to price before volume strategy**

\* source: LANXESS, average 2008 = 100%

Chart 34

**LANXESS**

# Business line Adipic Acid shifted to BU All

## Adipic Acid used captively and for external sales

In €m

Q2 2010

External sales

23

**EBIT**

7

D&A

0

**EBITDA**

7

▪ Adipic Acid sales split into:

- External sales
- Inter-BU sales
- BU Captive use

- Business line Adipic Acid transferred from Performance Polymers to Advanced Intermediates
- Originally located in BU SCP, now part of BU All
- Restatement reflects transfer of financials from Performance Polymers and addition to Advanced Intermediates as of Q1 2010

**Transfer of Adipic Acid:  
Value chain streamlined**

## Exceptional items incurred in Q2 2010 and Q2 2011

[€m]	Q2 2010		Q2 2011	
	Exceptional	thereof D&A	Exceptional	thereof D&A
Performance Polymers	1	0	0	0
Advanced Intermediates	0	0	0	0
Performance Chemicals	0	0	0	0
Reconciliation	3	0	5	0
<b>Total</b>	<b>4</b>	<b>0</b>	<b>5</b>	<b>0</b>

Chart 36

## Exceptional items incurred in H1 2010 and H1 2011

[€m]	H1 2010		H1 2011	
	Exceptional	thereof D&A	Exceptional	thereof D&A
Performance Polymers	2	0	0	0
Advanced Intermediates	0	0	0	0
Performance Chemicals	0	0	0	0
Reconciliation	5	0	10	0
<b>Total</b>	<b>7</b>	<b>0</b>	<b>10</b>	<b>0</b>

Chart 37

# Abbreviations

## Performance Polymers

- BTR Butyl Rubber
- PBR Performance Butadiene Rubbers
- TRP Technical Rubber Products
- SCP Semi-Crystalline Products

## Advanced Intermediates

- All\* Advanced Industrial Intermediates
- SGO Saltigo

## Performance Chemicals

- MPP Material Protection Products
- IPG Inorganic Pigments
- FCC Functional Chemicals
- LEA Leather
- RCH Rhein Chemie
- RUC Rubber Chemicals
- ION Ion Exchange Resins

\* formerly known as BAC (Basic Chemicals)

# Upcoming events 2011

## Upcoming events

- Analyst round table September 22, 2011
- Q3 Results 2011 November 10, 2011

# Contact detail Investor Relations

## **Oliver Stratmann**

**Head of Investor Relations**

Tel. : +49-214 30 49611  
Fax. : +49-214 30 959 49611  
Mobile : +49-175 30 49611  
Email : [Oliver.Stratmann@lanxess.com](mailto:Oliver.Stratmann@lanxess.com)



## **Verena Simiot**

**Assistant Investor Relations**

Tel. : +49-214 30 23851  
Fax. : +49-214 30 40944  
Mobile : +49-175 30 23851  
Email : [Verena.Simiot@lanxess.com](mailto:Verena.Simiot@lanxess.com)



## **Tanja Satzer**

**Private Investors / AGM**

Tel. : +49-214 30 43801  
Fax. : +49-214 30 959 43801  
Mobile : +49-175 30 43801  
Email : [Tanja.Satzer@lanxess.com](mailto:Tanja.Satzer@lanxess.com)



## **Constantin Fest**

**Institutional Investors / Analysts**

Tel. : +49-214 30 71416  
Fax. : +49-214 30 40944  
Mobile : +49-175 30 71416  
Email : [Constantin.Fest@lanxess.com](mailto:Constantin.Fest@lanxess.com)



## **Joachim Kunz**

**Institutional Investors / Analysts**

Tel. : +49-214 30 42030  
Fax. : +49-214 30 40944  
Mobile : +49-175 30 42030  
Email : [Joachim.Kunz@lanxess.com](mailto:Joachim.Kunz@lanxess.com)

